Michael Henry
Has grant
Professor and Chair
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Professor Michael Henry is a faculty member at the University of Iowa College of Medicine, USA. His research focuses on the mechanisms of cancer cell resistance, particularly regarding their ability to adapt to mechanical stress in circulation. Professor Henry has contributed significantly to the understanding of the RhoA/actomyosin pathway as a means of mechano-adaptation in cancer cells.
Recent Grants
Grant: Close
Improved detection of bladder cancer recurrence using a biophysical biomarker
Open Date: 2017-09-18
Close Date: 2020-01-31
Grant: Close
Effects of fluid shear stress on circulating tumor cells
Open Date: 2016-03-01
Close Date: 2018-02-28
Grant: Close
(PQC2) Resistance to fluid shear stress: a novel biomarker of cancer cells
Open Date: 2013-09-01
Close Date: 2016-02-29
Grant: Close
Novel Biophysical Marker of Aggressive Prostate Cancer Cells
Open Date: 2010-10-01
Close Date: 2011-09-01
Grant: Close
Effects of pesticides on prostate cancer progression in PTEN mutant mice
Open Date: 2009-09-25
Close Date: 2011-06-30
Articles (5)
Circulating tumor cells (CTCs) face challenges to their survival including mechanical and oxidative stresses that are different from cancer cells in solid primary and metastatic tumors. The impact of adaptations to the fluid microenvironment of the circulation on the outcome of the metastatic cascade are not well understood. Here we find that cancer cells (PC-3, MDA-MB-231, Myc-CaP) exposed to brief pulses of high-level FSS exhibit enhanced invasiveness and anchorage-independent proliferation in vitro and enhanced metastatic colonization/tumor formation in vivo . Cancer cells exposed to FSS rapidly alter their metabolism in a manner that promotes survival by providing energy for cytoskeletal remodeling and contractility as well as reducing equivalents to counter oxidative stress associated with cell detachment. Thus, exposure to FSS may provide CTCs an unexpected survival benefit that promotes metastatic colonization.
Year:
2025
/Summary Purpose Sarcomas are a heterogeneous group of cancers with few shared therapeutic targets. PI3K signaling is activated in various subsets of sarcomas, representing a shared oncogenic signaling pathway. Oncogenic PI3K signaling has been challenging to target therapeutically. An integrated view of PI3K and Hippo pathway signaling is examined to determine if this could be leveraged therapeutically. Experimental design A tissue microarray containing sarcomas of various histological types was evaluated for PTEN loss and correlated with levels of activated TAZ and YAP. PI3K and Hippo pathways were dissected in sarcoma cell lines. The role of TAZ and YAP were evaluated in a PI3K-driven mouse model. The efficacy of mTORC1 inhibition and TEAD inhibition were evaluated in sarcoma cell lines and in vivo . Results PI3K signaling is frequently activated in sarcomas due to PTEN loss (in 30-60%), representing a common therapeutic target. TAZ and YAP are transcriptional co-activators regulated by PI3K and drive a transcriptome necessary for tumor growth in a PI3K-driven sarcoma mouse model. Combination therapy using IK-930 (TEAD inhibitor) and everolimus (mTORC1 inhibitor) synergistically diminished proliferation and anchorage independent growth of PI3K-activated sarcoma cell lines at low, physiologically achievable doses. Furthermore, this combination therapy showed a synergistic effect in vivo , reducing tumor proliferation and size. Conclusions TAZ and YAP are transcriptional co-activators downstream of PI3K signaling, a pathway that has lacked a well-defined oncogenic transcription factor. This PI3K-TAZ/YAP axis exists in parallel to the known PI3K-Akt-mTORC1 axis allowing for synergistic combination therapy targeting the TAZ/YAP-TEAD interaction and mTORC1 in sarcomas.
Year:
2025
Melanoma cells have the ability to switch from a melanocytic and proliferative state to a mesenchymal and invasive state and back again. This plasticity drives intra-tumoral heterogeneity, progression, and therapeutic resistance. Microphthalmia-associated Transcription Factor (MITF) promotes the melanocytic/proliferative phenotype, but factors that drive the mesenchymal/invasive phenotype and the mechanisms that effect the switch between cell states are unclear. Here, we identify the MITF paralog TFE3 and the non-canonical mTORC1 pathway as regulators of the mesenchymal state. We show that TFE3 expression drives the metastatic phenotype in melanoma cell lines and tumors. Deletion of TFE3 in MITF-low melanoma cell lines suppresses their ability to migrate and metastasize. Further, MITF suppresses the mesenchymal phenotype by directly or indirectly activating expression of FNIP1, FNIP2, and FLCN , which encode components of the non-canonical mTORC1 pathway, thereby promoting cytoplasmic retention and lysosome-mediated degradation of TFE3. These findings highlight a molecular pathway controlling melanoma plasticity and invasiveness.
Year:
2024
Epithelial-mesenchymal transitions (EMTs) have emerged as a mechanism for carcinomas to gain metastatic capabilities. As classically defined, EMTs entail downregulation of E-cadherin, viewed as a master enforcer of an epithelial phenotype, and upregulation of mesenchymal markers such as N-cadherin and vimentin. Contrary to this, E-cadherin appears to be retained in many invasive carcinomas and promote collective cell invasion. Therefore, major questions remain concerning the role of E-cadherin in metastasis. To investigate how E-cadherin regulates metastasis, we selected murine 4T1 breast carcinoma cells, a widely utilized model of stage IV metastatic breast cancer that retains E-cadherin expression. Using RNA interference and constitutive expression, we demonstrate that the expression level of E-cadherin does not determine 4T1 metastatic capacity in mice. Despite high levels of expression, E-cadherin is unable to confer an epithelial phenotype with stable organized cell-cell junctions. Moreover, orthotopic 4T1 tumors in mice display co-expression of E-cadherin and vimentin and contain subregions of EMT-like loss of E-cadherin. In addition, we find that 4T1 cells co-express epithelial and mesenchymal isoforms of p120-catenin. These findings support 4T1 cells as a model for carcinomas that possess hybrid traits of epithelial and mesenchymal states that promote invasion and metastasis. As such, the 4T1 model provides a platform for investigating strategies to reinstate E-cadherin’s ability to promote stable cell-cell junctions in E-cadherin-positive cancers, and for identifying which aspects of an epithelial phenotype may serve to facilitate the macroscopic growth of metastatic colonies.
Year:
2024
Year:
2020
Collaborators (2)
Colin Kenny
Assistant Professor
The University of Iowa
Munir Tanas
Professor
The University of Iowa
Make your next move.
Prepare your application
Review drafts before you send them.